<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vaxcyte Inc — News on 6ix</title>
<link>https://6ix.com/company/vaxcyte-inc</link>
<description>Latest news and press releases for Vaxcyte Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vaxcyte-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835aa0178dffbe2df10d011.webp</url>
<title>Vaxcyte Inc</title>
<link>https://6ix.com/company/vaxcyte-inc</link>
</image>
<item>
<title>Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company</description>
</item>
<item>
<title>Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-completes-enrollment-of-opus-1-and-opus-2-phase-3-trials-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumonia-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-completes-enrollment-of-opus-1-and-opus-2-phase-3-trials-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumonia-in-adults</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and</description>
</item>
<item>
<title>Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate</title>
<link>https://6ix.com/company/vaxcyte-inc/news/positive-vax-31-phase-12-adult-data-published-in-the-lancet-infectious-diseases-highlight-best-in-class-potential-of-vaxcytes-31-valent-pneumococcal-conjugate-vaccine-pcv-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/positive-vax-31-phase-12-adult-data-published-in-the-lancet-infectious-diseases-highlight-best-in-class-potential-of-vaxcytes-31-valent-pneumococcal-conjugate-vaccine-pcv-candidate</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into</description>
</item>
<item>
<title>Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Boos</description>
</item>
<item>
<title>Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-doses-first-participants-opus-210500697</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-doses-first-participants-opus-210500697</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to Enroll Subjects, with Topline Data Expected in Fourth Quarter of 2026 Vaxcyte’s VAX-31 Phase 3 Adult Clinical Program – Finalized in Consultation and Alignment with U.S. Food and Drug Administration – to Support Planned BLA Submission VAX-31 is Design</description>
</item>
<item>
<title>Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-report-fourth-quarter-full-210500832</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-report-fourth-quarter-full-210500832</guid>
<pubDate>Tue, 10 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (internation</description>
</item>
<item>
<title>Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-present-guggenheim-emerging-outlook-210500829</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-present-guggenheim-emerging-outlook-210500829</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webc</description>
</item>
<item>
<title>Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-closing-632-5-210500981</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-closing-632-5-210500981</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts</description>
</item>
<item>
<title>Vaxcyte Announces Pricing of $550 Million Public Offering</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-pricing-550-million-043300981</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-pricing-550-million-043300981</guid>
<pubDate>Fri, 30 Jan 2026 04:33:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expense</description>
</item>
<item>
<title>Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-commencement-proposed-public-210600165</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-commencement-proposed-public-210600165</guid>
<pubDate>Thu, 29 Jan 2026 21:06:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock of</description>
</item>
<item>
<title>Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-advances-adult-and-infant-programs-vax-31-potential-best-class-next</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-advances-adult-and-infant-programs-vax-31-potential-best-class-next</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine</description>
</item>
<item>
<title>Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-doses-first-participants-opus-phase-3-noninferiority-trial-evaluating-vax-31</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-doses-first-participants-opus-phase-3-noninferiority-trial-evaluating-vax-31</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal</description>
</item>
<item>
<title>Medicxi Announces €500 Million Fund V</title>
<link>https://6ix.com/company/vaxcyte-inc/news/medicxi-announces-euro500-million-fund-v</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/medicxi-announces-euro500-million-fund-v</guid>
<pubDate>Fri, 14 Nov 2025 08:00:00 GMT</pubDate>
<description>Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.</description>
</item>
<item>
<title>Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting</description>
</item>
<item>
<title>Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-establish-fill-finish-manufacturing-north-carolina-key-element-long-term</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-establish-fill-finish-manufacturing-north-carolina-key-element-long-term</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal</description>
</item>
<item>
<title>Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-advances-vax-31-infant-phase-2-dose-finding-study-first-participants</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-advances-vax-31-infant-phase-2-dose-finding-study-first-participants</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant</description>
</item>
<item>
<title>Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as</description>
</item>
<item>
<title>Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-first-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-reports-first-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of</description>
</item>
<item>
<title>Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-appoints-dr-olivier-brandicourt-board-directors-2025-05-01</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-appoints-dr-olivier-brandicourt-board-directors-2025-05-01</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect</description>
</item>
<item>
<title>Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study</title>
<link>https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-positive-topline-results-vax-24-infant-phase-2-dose-finding-study</link>
<guid isPermaLink="true">https://6ix.com/company/vaxcyte-inc/news/vaxcyte-announces-positive-topline-results-vax-24-infant-phase-2-dose-finding-study</guid>
<pubDate>Mon, 31 Mar 2025 04:00:00 GMT</pubDate>
<description>-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses</description>
</item>
</channel>
</rss>